Show simple item record

dc.contributor.authorLegros, D
dc.contributor.authorFournier, C
dc.contributor.authorGastellu-Etchegorry, M
dc.contributor.authorMaiso, F
dc.contributor.authorSzumilin, E
dc.date.accessioned2008-04-14T11:18:43Z
dc.date.available2008-04-14T11:18:43Z
dc.date.issued1999-07
dc.identifier.citation[Therapeutic Failure of Melarsoprol Among Patients Treated for Late Stage T.b. Gambiense Human African Trypanosomiasis in Uganda] 1999, 92 (3):171-2notBull Soc Pathol Exoen
dc.identifier.issn0037-9085
dc.identifier.pmid10472443
dc.identifier.urihttp://hdl.handle.net/10144/23218
dc.description.abstractThe failure rate of melarsoprol after treatment of late stage cases of Human African Trypanosomiasis (HAT) is usually under 7%, even though the drug has been used for such treatment over the past 50 years. We report a melarsoprol treatment failure rate of 26.9% among 428 patients treated in Northern Uganda. Whatever its origin, this observation, the first documented in a HAT focus, is alarming, particularly since no second line trypanocidal drug is actually available for the treatment of late stage HAT. We believe that the current worrisome situation of HAT in several African countries and the risk of emergence of other foci of resistance, argue in favour of a greater attention on the part of the scientific community and the pharmaceutical companies being paid to this problem.
dc.languagefre
dc.language.isofren
dc.rightsArchived with thanks to Bulletin de la Société de Pathologie Exotique (1990)en
dc.subject.meshDrug Resistanceen
dc.subject.meshHumansen
dc.subject.meshMelarsoprolen
dc.subject.meshTreatment Failureen
dc.subject.meshTrypanocidal Agentsen
dc.subject.meshTrypanosomiasis, Africanen
dc.subject.meshUgandaen
dc.titleTherapeutic Failure of Melarsoprol Among Patients Treated for Late Stage T.b. Gambiense Human African Trypanosomiasis in Ugandafr
dc.contributor.departmentEpicentre, Kampala, Ouganda. epi@imul.comen
dc.identifier.journalBulletin de la Société de Pathologie Exotique (1990)en
refterms.dateFOA2019-03-04T09:52:49Z
html.description.abstractThe failure rate of melarsoprol after treatment of late stage cases of Human African Trypanosomiasis (HAT) is usually under 7%, even though the drug has been used for such treatment over the past 50 years. We report a melarsoprol treatment failure rate of 26.9% among 428 patients treated in Northern Uganda. Whatever its origin, this observation, the first documented in a HAT focus, is alarming, particularly since no second line trypanocidal drug is actually available for the treatment of late stage HAT. We believe that the current worrisome situation of HAT in several African countries and the risk of emergence of other foci of resistance, argue in favour of a greater attention on the part of the scientific community and the pharmaceutical companies being paid to this problem.


Files in this item

Thumbnail
Name:
legros.pdf
Size:
212.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record